<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Pediatrics: Pharmacogenetics/Pharmacogenomics Topic Collection</title>
    <link>http://archpedi.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Wed, 09 May 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:50:56 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archpedi.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archpedi.jamanetwork.com</webMaster>
    <item>
      <title>Evaluating Pharmacogenetic Tests A Case Example </title>
      <link>http://archpedi.jamanetwork.com/article.aspx?articleID=485652</link>
      <pubDate>Mon, 01 Mar 2004 00:00:00 GMT</pubDate>
      <author>Freund CL, Gregory DF, Clayton E. </author>
      <description>&lt;span class="paragraphSection"&gt;Work in human genetics is revealing genes that affect the safe and effective use of pharmaceuticals. Primary care physicians are already receiving advertisements for tests for these variations that emphasize the value of learning about their patients' susceptibility to adverse reactions in order to avoid them. We propose a strategy for the critical evaluation of such offers to ensure the optimal use of these tests.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">158</prism:volume>
      <prism:number xmlns:prism="prism">3</prism:number>
      <prism:startingPage xmlns:prism="prism">276</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">279</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archpedi.158.3.276</prism:doi>
      <guid>http://archpedi.jamanetwork.com/article.aspx?articleID=485652</guid>
    </item>
  </channel>
</rss>